SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
173.10
-3.13 (-1.78%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close176.23
Open176.42
Bid170.62 x 900
Ask176.97 x 800
Day's Range171.43 - 176.50
52 Week Range146.80 - 179.84
Volume1,203,597
Avg. Volume1,230,495
Market Cap64.738B
Beta (3Y Monthly)0.26
PE Ratio (TTM)61.12
EPS (TTM)2.83
Earnings DateOct 25, 2018
Forward Dividend & Yield1.88 (1.07%)
Ex-Dividend Date2018-09-27
1y Target Est187.27
Trade prices are not sourced from all markets
  • Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings
    Market Realist16 hours ago

    Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings

    Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.

  • What Analysts Expect for Boston Scientific Stock
    Market Realist21 hours ago

    What Analysts Expect for Boston Scientific Stock

    Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.

  • What Can We Expect from Tandem’s Bottom Line in Third Quarter?
    Market Realist21 hours ago

    What Can We Expect from Tandem’s Bottom Line in Third Quarter?

    Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.

  • Stryker (SYK) Q3 Earnings Preview: What's in the Cards?
    Zacks21 hours ago

    Stryker (SYK) Q3 Earnings Preview: What's in the Cards?

    Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What Will BSX’s Q3 Operational Performance Look Like?
    Market Realist21 hours ago

    What Will BSX’s Q3 Operational Performance Look Like?

    Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.

  • Gauging Analysts’ Views on Varian Stock
    Market Realistyesterday

    Gauging Analysts’ Views on Varian Stock

    Three of the nine analysts covering Varian Medical Systems (VAR) in October have given the stock “strong buy” ratings, three have given it “hold” ratings, and three have given it “sell” ratings.

  • What to Expect from Varian’s Bottom Line in Q4 2018
    Market Realist2 days ago

    What to Expect from Varian’s Bottom Line in Q4 2018

    Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018 compared to $82.7 million in the fourth quarter of fiscal 2017, a rise of 27.02%. The company’s net income translates to a net income per share of $1.13 in the fourth quarter of fiscal 2018 compared to $0.89 in the fourth quarter of fiscal 2017. Varian Medical Systems generated free cash flow of $340.0 million in fiscal 2017.

  • How Varian’s Operational Performance Is Expected to Look in Q4
    Market Realist2 days ago

    How Varian’s Operational Performance Is Expected to Look in Q4

    Varian’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 44.23% and 44.15%, respectively. In comparison, the fiscal 2018 gross margins of its peers Globus Medical (GMED), Stryker (SYK), and Zimmer Biomet Holdings (ZBH) are expected to be 77.01%, 66.27%, and 71.91%, respectively. Varian Medical Systems is expected to incur selling, general, and administrative expenses of $140.77 million in the fourth quarter of fiscal 2018 compared to $51.70 million in the fourth quarter of fiscal 2017, a rise of more than 100%.

  • GlobeNewswire4 days ago

    MERGER ALERT – EGN, KTWO and RLJE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Oct. 15, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.

  • GlobeNewswire4 days ago

    Analysis: Positioning to Benefit within PTC, H&R Block, GenMark Diagnostics, American International Group, Newmont Mining, and Stryker — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • How Intuitive’s Bottom Line Is Expected to Look in Q3 2018
    Market Realist9 days ago

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% from $227.5 million in the third quarter of 2017 to $265.76 million in the third quarter of 2018. In the third quarter, Intuitive Surgical is expected to incur selling, general, and administrative expenses of $207.11 million compared to $204.8 million in the third quarter of 2017, reflecting a potential increase of 1.13%. Intuitive Surgical is expected to report net income of $258.28 million in the third quarter compared to net income of $297.5 million in the third quarter of 2017, indicating a contraction of 13.18% in the company’s net margins.

  • Why Most Analysts Are Bullish on Intuitive Surgical in October
    Market Realist9 days ago

    Why Most Analysts Are Bullish on Intuitive Surgical in October

    Eleven of the 18 analysts covering Intuitive Surgical (ISRG) in October have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one has given it a “sell” rating.

  • General Dynamics' Unit Wins Arms Deal for Stryker Vehicles
    Zacks10 days ago

    General Dynamics' Unit Wins Arms Deal for Stryker Vehicles

    General Dynamics' (GD) Stryker Family of armored combat vehicles provides the U.S. Army with an effective mix of capabilities, including infantry transport, offensive firepower and reconnaissance

  • General Dynamics Wins $367M Army Deal for Upgrading Stryker
    Zacks11 days ago

    General Dynamics Wins $367M Army Deal for Upgrading Stryker

    General Dynamics' (GD) Stryker Land Vehicle assists the U.S. Army with capabilities that include infantry transport, offensive firepower and reconnaissance.

  • Stryker's HyperBranch Buyout to Boost Neurotechnology Business
    Zacks16 days ago

    Stryker's HyperBranch Buyout to Boost Neurotechnology Business

    Stryker's (SYK) craniomaxillofacial division's market prospects bright.

  • The Wall Street Journal18 days ago

    [$$] Stryker Buys HyperBranch for $220 Million

    Stryker Corp. on Monday said it acquired venture-backed medical-device maker HyperBranch Medical Technology Inc. in an all-cash deal valued at about $220 million.

  • What ResMed’s Valuation Trend Indicates
    Market Realist21 days ago

    What ResMed’s Valuation Trend Indicates

    Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.

  • What’s the Upside Potential for Agilent Technologies Stock?
    Market Realist21 days ago

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018. The enterprise value of Agilent is $22.11 billion, and its enterprise-value-to-revenue ratio is 4.6x. Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 3.6x.

  • Agilent’s Top Line Expected to Stay on Upward Trajectory
    Market Realist22 days ago

    Agilent’s Top Line Expected to Stay on Upward Trajectory

    Agilent Technologies (A) generated total revenues of $1.2 billion in the third quarter of 2018 compared to $1.11 billion in the third quarter of 2017. Agilent generates revenues from product sales and services. For fiscal 2018 and 2019, Agilent is expected to generate revenues of $4.88 billion and $5.18 billion, respectively, compared to $4.47 billion in fiscal 2017.

  • What Waters Corporation’s Valuation Trend Indicates
    Market Realist22 days ago

    What Waters Corporation’s Valuation Trend Indicates

    The mean rating for Waters Corporation stock is 2.8, and its target price is $205.79, implying an upside potential of 5.7% over its closing price of $194.69 on September 26. In comparison, for peers Danaher (DHR), Stryker (SYK), and Thermo Fisher Scientific (TMO), analysts have mean ratings of 1.83, 1.93, and 1.63, respectively, and target prices of $114.07, $184.43, and $252.86, respectively. From its level of $218.70 on January 29, the stock corrected to $186.44 on August 15.

  • How Waters Corporation Is Positioned in 2018
    Market Realist22 days ago

    How Waters Corporation Is Positioned in 2018

    Waters Corporation (WAT) is a specialty measurement company and a pioneer in analytical workflow solutions that involve liquid chromatography, mass spectrometry, and thermal analysis innovations. Additionally, Waters Corporation’s thermal analysis, rheometry, and calorimetry instruments are used in predicting the stability and suitability of fine chemicals, pharmaceuticals, water, polymers, and viscous liquids. Waters Corporation generated total revenue of $596.22 million in the second quarter compared to $558.25 million in the comparable period of 2017.

  • GlobeNewswire28 days ago

    MERGER ALERT – IVTY, EGL and ESND: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...

  • What’s the Upside Potential of Thermo Fisher Scientific Stock?
    Market Realistlast month

    What’s the Upside Potential of Thermo Fisher Scientific Stock?

    So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.

  • What Thermo Fisher Scientific’s Gross Margin Trend Indicates
    Market Realistlast month

    What Thermo Fisher Scientific’s Gross Margin Trend Indicates

    Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.

  • GlobeNewswirelast month

    MERGER ALERT – IVTY and EGL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Sept. 14, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...